Pharma
World EPA Congress 2027
Evidence, Pricing and Access is Europe’s largest congress in market access, pricing and evidence featuring 250 speakers, multiple streams and over 1500 attendees from pharma, biotech and Payers/ HTA’s.
86Speakers
0Sponsors
1Exhibitors
90Sessions
78Companies · in total
Get alerts for World EPA Congress 2027
- Reminders 90, 30, 7 and 1 day before it starts
- Add the companies you sell to and see when they sponsor or speak
Speakers
Programmed at World, in alphabetical order.
Adam Gordois
Director, Value Demonstration & HEOR · BioCryst Pharmaceuticals
Adam PARNABY
Lead, Global Policy & Access · Bristol Myers Squibb
Ad Antonisse
Director, Market Access & Corporate Affairs · AstraZeneca
Adriana Robayo
Executive Director · Instituto de Evaluacin Tecnolgica en Salud (IETS)
Alessandro Monaco
General Manager · Oliba Healthcare and Pharma
Alexander Grosvenor
Senior Vice President, Managing Director · Precision Value & Health
Alexander Natz
Secretary General · EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Alex Bastian
Vice President, Commercial Strategy · Memo Therapeutics
Allister Upton
Value & Access Manager · Novo Nordisk
Amy Israel
Senior Advisor, Access to Medicines · Union for International Cancer Control
Ana Filipa Alexandre
Senior Director, Pipeline Head for Neuroscience · Teva Pharmaceuticals
Anh Bourcet Nguyen
International Director, Government Affairs and Policy, Rare Diseases · AstraZeneca
Anna Vicere
Director, Access Policy & Public Affairs · Vaccines Europe
Anne Willemsen
Chair JCA Subgroup · Zorginstituut Nederland
Antonella Cardone
CEO · Cancer Patients Europe
Aveline Godard
Head of Global Pricing & Tendering · Ferring
Ayman Semaan
Head of Market Access & Pricing · Biologix
Brad Groves
Director, NICE Advice · National Institute for Health & Care Excellence (NICE)
Bruno Cherel
Senior Director, Head of Pricing · Jazz Pharmaceuticals
Caroline van der Meijden
Director · iMTA
Christoph Glaetzer
Chief Global Value and Access Officer · Johnson & Johnson Innovative Medicine
Elizabeth Kinter
Vice President, Head of Global Market Access · Avidity BioSciences
Agenda
Selected from 90 sessions.
- Mar 2 10:20Plenary
Keynote: Reframing evidence planning for rare diseases in the JCA era - TBC
Session led by Parexel International LLC
- Mar 210:20Keynotes
Keynote: Reframing evidence planning for rare diseases in the JCA era - TBC
- Mar 2 10:40Plenary
Keynote: Access by design: Embedding access into core development decisions - TBC
Session led by Valid Insight
- Mar 210:40Keynotes
Keynote: Access by design: Embedding access into core development decisions - TBC
- Mar 2 12:15Track 1 (Market Access)
Chair's opening remarks
Session led by Access Infinity
- Mar 2 12:20Track 1 (Market Access)
Actionable Frameworks for Rapid Market Access Planning
- Mar 2 12:20Track 8 (Artificial Intelligence & Data)
AI-Enabled automation of evidence synthesis for modelling and value dossiers: SLR, feasibility assessment, ITC, and medical writing - TBC
- Mar 2 12:20Track 6 (Reimbursement)
AI will decide who gets access: why drug contracting is becoming pharma’s most strategic capability - TBC
- Mar 2 12:20Track 5 (Real World Evidence & Data)
Anchoring evidence-based decisions in a volatile policy landscape: strategic considerations for EU HTAR - TBC
Company intelligence
An audience of 78 companies, parsed from the program.
78 companies in attendance.
The numbers below are derived from the speakers, sponsors, and exhibitors on this page, cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.